Recombinant Urate Oxidase (Rasburicase) for the Prevention and Treatment of Tumor Lysis Syndrome in Patients with Hematologic Malignancies

Publisher： Karger

E-ISSN： 1421-9662|115|1-2|35-38

ISSN： 0001-5792

Source： Acta Haematologica, Vol.115, Iss.1-2, 2006-01, pp. : 35-38

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Acute Tumor Lysis Syndrome during Oral Fludarabine Treatment for Chronic Lymphocytic Leukemia. Role of Treatment with Rasburicase

By  

Oncology Research and Treatment, Vol. 31, Iss. 4, 2008-03 ,pp. : 197-199

Karger

Access to resources Recommend Favorite

Acute Tumor Lysis Syndrome – a Rare Complication in the Treatment of Solid Tumors

By  

Oncology Research and Treatment, Vol. 33, Iss. 10, 2010-09 ,pp. : 498-499

Karger

Access to resources Recommend Favorite

Infectious Port Complications Are More Frequent in Younger Patients with Hematologic Malignancies than in Solid Tumor Patients

By  

Oncology, Vol. 74, Iss. 3-4, 2008-08 ,pp. : 237-244

Karger

Access to resources Recommend Favorite

Acute kidney injury from tumour lysis syndrome and urate crystalluria

By  

BRITISH JOURNAL OF HAEMATOLOGY, Vol. 170, Iss. 4, 2015-08 ,pp. : 444-444

John Wiley & Sons Inc

Access to resources Recommend Favorite

Management of Hyperleukocytosis and Prevention of Tumor Lysis Syndrome with Low-Dose Prednisone Continuous Infusion in Children with Acute Lymphoblastic Leukemia

By  

Acta Haematologica, Vol. 121, Iss. 1, 2009-04 ,pp. : 56-62

Karger

Access to resources Recommend Favorite